{"id":66325,"date":"2026-05-26T14:22:04","date_gmt":"2026-05-26T06:22:04","guid":{"rendered":"https:\/\/flcube.com\/?p=66325"},"modified":"2026-05-26T14:22:05","modified_gmt":"2026-05-26T06:22:05","slug":"eli-lilly-reports-positive-phase-1b-results-for-verve-102-base-editing-therapy-with-sustained-ldl-c-reductions-up-to-18-months","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66325","title":{"rendered":"Eli Lilly Reports Positive Phase 1b Results for VERVE-102 Base Editing Therapy with Sustained LDL-C Reductions Up to 18 Months"},"content":{"rendered":"\n

Eli Lilly and Company<\/strong> (NYSE: LLY<\/a>) announced positive interim results<\/strong> from the Phase 1b Heart-2 study<\/strong> of VERVE-102<\/strong>, an investigational in vivo base editing medicine<\/strong> designed to durably turn off the PCSK9 gene<\/strong> in the liver and lower low-density lipoprotein cholesterol (LDL-C)<\/strong> following a single infusion<\/strong>.<\/p>\n\n\n\n

Clinical Trial Highlights \u2013 Phase 1b Heart-2 Study<\/h2>\n\n\n\n
Key Metric<\/th>Results<\/th><\/tr><\/thead>
Study Population<\/strong><\/td>35 adults with heterozygous familial hypercholesterolemia (HeFH) or premature coronary artery disease (CAD)<\/td><\/tr>
Treatment<\/strong><\/td>Single intravenous infusion of VERVE-102 at doses ranging from 0.3\u20131.0 mg\/kg<\/td><\/tr>
Primary Outcomes<\/strong><\/td>Dose-dependent reductions in PCSK9 protein and LDL-C across all dose levels<\/td><\/tr>
Durability<\/strong><\/td>Sustained effects observed for up to 18 months<\/strong> post-treatment<\/td><\/tr>
Safety<\/strong><\/td>Well tolerated across all dose levels with no significant safety concerns<\/td><\/tr>
Next Steps<\/strong><\/td>Phase 2 clinical study initiation planned by end of 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Dose-Response Relationship \u2013 Interim Analysis<\/h2>\n\n\n\n
Dose Level (mg\/kg)<\/th>Mean PCSK9 Reduction<\/th>Mean LDL-C Reduction<\/th><\/tr><\/thead>
0.3<\/strong><\/td>51%<\/td>9%<\/td><\/tr>
0.45<\/strong><\/td>Not specified<\/td>44%<\/td><\/tr>
0.6<\/strong><\/td>Not specified<\/td>45%<\/td><\/tr>
0.7<\/strong><\/td>Not specified<\/td>33%<\/td><\/tr>
0.8<\/strong><\/td>Not specified<\/td>51%<\/td><\/tr>
1.0<\/strong><\/td>88%<\/td>62%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The data demonstrate a clear dose-dependent relationship<\/strong> with the highest dose (1.0 mg\/kg) achieving 88% reduction in PCSK9<\/strong> and 62% reduction in LDL-C<\/strong>, sustained for up to 18 months following a single administration.<\/p>\n\n\n\n

Technology Platform & Innovation Profile<\/h2>\n\n\n\n